University of Surrey

Test tubes in the lab Research in the ATI Dance Research

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

Pandha, HS, Protheroe, A, Wylie, J, Parker, C, Chambers, J, Bell, S and Munzert, G (2008) An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC) JOURNAL OF CLINICAL ONCOLOGY, 26 (15).

Full text not available from this repository.
Item Type: Article
Authors :
NameEmailORCID
Pandha, HSh.pandha@surrey.ac.ukUNSPECIFIED
Protheroe, AUNSPECIFIEDUNSPECIFIED
Wylie, JUNSPECIFIEDUNSPECIFIED
Parker, CUNSPECIFIEDUNSPECIFIED
Chambers, JUNSPECIFIEDUNSPECIFIED
Bell, SUNSPECIFIEDUNSPECIFIED
Munzert, GUNSPECIFIEDUNSPECIFIED
Date : 20 May 2008
Uncontrolled Keywords : Science & Technology, Life Sciences & Biomedicine, Oncology
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 09:46
Last Modified : 17 May 2017 14:44
URI: http://epubs.surrey.ac.uk/id/eprint/825078

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800